What is WGS's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 2.05B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for WGS?

P/E (TTM) is n/a and 52-week range is $32.21 to $170.87 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s WGS figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for WGS?

The company profile lists revenue (TTM) near $454M, net income (TTM) near $-10.63B, EPS (TTM) near $-3.63 when available from the market-data feed. Figures are informational and may lag live markets.

Where is GeneDx Holdings Corp based, and what identifiers does Chartloom list?

The company context section lists headquarters in Stamford, Connecticut, US, 29.7M shares outstanding, ISIN US81663L2007 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

GeneDx Holdings Corp

$WGS

Health Care · Health Care Providers & Services

IR Run Scenarios

$68.61

+5.62%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

GeneDx Holdings Corp. operates as a health intelligence company. The company is headquartered in Stamford, Connecticut and currently employs 1,300 full-time employees. The company went IPO on 2020-09-04. The firm operates, through its subsidiary, GeneDx, LLC, which is focused on exome and genome tests that translate complex genomic data into clinical answers that unlock personalized health plans, accelerate drug discovery, and improve health system efficiencies. The company operates through GeneDx segment, which primarily provides pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing and, to a lesser extent, data and information services. Exome sequencing test options include XomeDx, XomeDx Plus, and XomeDxXpress. GeneDx genome sequencing evaluates the protein-coding and non-coding regions of an individual’s nuclear genome. GeneDx genome sequencing test options include GenomeSeqDx and GenomeXpress. The company offers a menu of targeted variant testing options to meet the needs of families and healthcare providers. Its subsidiary, Fabric Genomics, Inc., specializes in artificial intelligence-powered genomic interpretation.

Employees

1,300

Website

sema4.com/

IPO

2020-09-04

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)